Skip to main content

DiMe Publications

FDA Diversity Plan Clinical Trials

A letter submitted on behalf of the Digital Medicine Society (DiMe) for consideration by the U.S. Food and Drug Administration (FDA) regarding Docket No. FDA-2021-D-0789 for “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability.”

June 2022

Join our next project

Help streamline the path to regulatory and commercial success to optimize health outcomes for the greatest number of patients

Join the Integrated Evidence Plans project

Join us
Not today